COMMENTARY

• 7 Drugs Picked for Cost-Effective Assessments, but Now How Will They Be Re-Priced Exactly?
  May 27, 2016

• Data Corroborate Harshness of Z2 Rule, Only Handful to Escape 2nd Consecutive Application
  March 31, 2016

• Global Pharmas Casting Colder Eyes on Japan Market; PhRMA, EFPIA to Up Lobbying Efforts with Govt, Ruling Parties
  March 11, 2016

• Companies Can “Veto” Humanitarian Trials for Legitimate Reasons; Cooperation Is Essential, but Access Scheme Shouldn’t Stymie Main Development
  February 23, 2016

• It’s Time to Squarely Discuss Proposed Penalty through Drug Price Cuts
  February 3, 2016

• Generic Industry’s Tactic to Thwart 50% Pricing Rule Draws Mixed Reviews
  January 18, 2016

• Is 7.8% Drug Cost Cut Justifiable? Make “Huge Seller” Re-Pricing a Starter to Discuss This
  January 12, 2016

• High Hopes for New Osteoporosis Drugs, but “Treatment Gap” Needs to Be Addressed
  November 27, 2015

• Sakigake Designation System to Link Regulatory and Drug Pricing Systems; Could Result in Tougher Scrutiny for Designated Products
  November 6, 2015

• Data from Humanitarian Trials to Be Used in Product Reviews; Effective Use of Safety-Related Information Will Be Key
  October 13, 2015

• Japan, US, EU Regulators Trod Different Paths to Iressa Approval; Japan’s Capabilities to Be Tested with Sakigake System
  September 24, 2015

• How Will Industry Counter Proposed Re-Pricing of “Huge Seller” Drugs?
  August 18, 2015

• Leaner Sales Forces? Lower Profits? Drug Makers Face Tough Decision in 80% Generic Era
  August 14, 2015

• PMDA Poised to Tap Big Data to Refine Reviews, Safety Steps; Dedicated Center Eyed in 2018
  August 12, 2015

• Wholesalers Face Pressing Need to Retool Biz Strategy as Generics Gain Ground
  July 21, 2015

• Viable Third-Party Review System Required for Drug Makers’ Advertisements
  July 7, 2015

• Japan Compassionate Use System a “Stick” for Drug Makers? Incentives to Counter Their Burden Needed
  June 22, 2015

• Generic Makers Baffled by New Govt Target, Quality and Supply Concerns Linger
  June 15, 2015

• Thorny Path Ahead toward Trial Rollout of Cost-Effective Assessment in FY2016; Chuikyo to Begin Discussions on May 27
  May 26, 2015

• 1 Year after Viagra Generic Debut, Freely Priced Generics Seem to Be Bringing Benefits
  May 8, 2015

ページ